David H. Johnson

Q: What Schools Are Affiliated With David H. Johnson

David H. Johnson is affiliated with the following schools: Dalhousie University, Vanderbilt University, University of Toronto, University of Texas Southwestern Medical Center, University of Pennsylvania, Heidelberg University

David H. Johnson's AcademicInfluence.com Rankings

David H. Johnson

Philosophy

#8335

World Rank

#11692

Historical Rank

Logic

#5368

World Rank

#6761

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David H. Johnson's Degrees

Doctorate Medicine Harvard University

Why Is David H. Johnson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David H. Johnson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (2006) (5665)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (2002) (4832)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. (2004) (1937)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (2004) (1790)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004) (1779)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005) (1538)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. (2005) (1488)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. (2005) (1409)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. (2004) (1383)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial (2009) (1199)
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer (1991) (1086)
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009) (870)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016) (705)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. (2005) (533)
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. (2002) (506)
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. (2011) (494)
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group (2000) (444)
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 (2005) (379)
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). (2007) (377)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015) (373)
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. (2002) (356)
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. (2010) (353)
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. (2008) (350)
Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer (2000) (317)
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. (2007) (316)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (284)
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study (2008) (267)
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. (2015) (263)
Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) (2005) (255)
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2011) (253)
Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. (2005) (246)
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 (2001) (245)
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. (2007) (223)
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. (2010) (222)
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models (2007) (211)
Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. (1986) (209)
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. (2004) (202)
Hot flashes and related outcomes in breast cancer survivors and matched comparison women. (2002) (197)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016) (176)
Tyrosine kinase inhibitors—ZD1839 (Iressa) (2001) (172)
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. (2004) (171)
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma (2001) (169)
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. (2011) (166)
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. (2004) (164)
Metastatic breast cancer confined to the skeletal system. An indolent disease. (1986) (159)
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. (2005) (155)
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. (2009) (150)
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. (2009) (145)
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) (2007) (143)
Improving the evaluation of new cancer treatments: challenges and opportunities (2003) (140)
Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594 (2006) (132)
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. (2005) (129)
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer (2004) (129)
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. (2003) (124)
Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel (2005) (121)
Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations (1985) (120)
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. (2003) (115)
Diagnostic Accuracy of MALDI Mass Spectrometric Analysis of Unfractionated Serum in Lung Cancer (2007) (112)
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. (2006) (110)
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. (2013) (106)
O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (70–80 yrs) with NSCLC do as well as younger patients (<70) (2003) (106)
Non-small cell lung cancer. (2010) (103)
Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (2005) (95)
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma (2005) (95)
Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. (2006) (94)
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. (2004) (93)
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. (2010) (88)
Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials (2013) (87)
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. (2002) (84)
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. (2007) (81)
A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer (2009) (79)
Expression of β-catenin, α-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas (1998) (78)
Advanced Minimal Residual Ovarian Carcinoma: Abdominopelvic Irradiation Following Combination Chemotherapy (1983) (74)
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. (2008) (72)
Breast cancer with skeletal metastases at initial diagnosis: Distinctive clinical characteristics and favorable prognosis (1986) (68)
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. (2003) (66)
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer (2011) (66)
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer (2006) (66)
High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study. (1984) (65)
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. (2007) (64)
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. (2005) (63)
Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. (2005) (62)
Improved Survival with Neoadjuvant Therapy and Resection for Adenocarcinoma of the Esophagus (1993) (62)
Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990 (2006) (61)
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. (2002) (58)
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. (2006) (56)
Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis (2012) (55)
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib (2008) (54)
Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). (2010) (54)
A randomized Phase II trial in patients with carcinoma of an unknown primary site (2001) (53)
A brief‐duration combination chemotherapy for elderly patients with poor‐prognosis non‐Hodgkin's lymphoma (1991) (53)
Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP‐16) (1986) (50)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
Current status of etoposide in the management of small cell lung cancer (1991) (49)
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? (2003) (47)
Gefitinib (Iressa) trials in non-small cell lung cancer. (2003) (46)
Chronic oral etoposide (1991) (46)
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
109 RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable now small cell lung cancer with minimum three year follow-up (1995) (46)
Late recurrences in long‐term survivors of germ cell neoplasms (1988) (46)
High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. (1983) (45)
Oncogenic Mutations Regulate Tumor Microenvironment through Induction of Growth Factors and Angiogenic Mediators (2010) (42)
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. (2012) (41)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. (2017) (40)
Chemotherapy in small cell lung cancer: a consensus report (1989) (40)
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. (2009) (40)
Disseminated Merkel Cell Tumor Treatment with Systemic Chemotherapy (1987) (39)
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. (2012) (39)
EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer (2006) (39)
Cytoplasmic Clusterin Expression Is Associated with Longer Survival in Patients with Resected Non–Small Cell Lung Cancer (2007) (37)
A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report (2005) (36)
Evarts A. Graham and the first pneumonectomy for lung cancer. (2008) (35)
Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. (1985) (33)
Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States. (2011) (32)
Prevalence and Prognostic Significance of Neuroendocrine Cells in Esophageal Adenocarcinoma (2000) (31)
O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 (2005) (31)
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer (2018) (30)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study (2010) (29)
Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. (2013) (29)
A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive‐stage small cell lung cancer (1992) (29)
Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report (1991) (28)
Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. (2008) (28)
ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) (2004) (26)
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial (2014) (26)
Treatment and Outcomes for Elderly Patients with Small Cell Lung Cancer (2000) (26)
Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590) (2000) (25)
Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non‐hodgkin's lymphoma (1991) (25)
Combined modality therapy in non‐small cell lung cancer (1995) (25)
Staging Lung Carcinoma with a Tc‐99m Labeled Monoclonal Antibody (1992) (24)
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. (2004) (24)
EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial (2005) (24)
High-dose etoposide (VP-16) in small-cell lung cancer. (1985) (24)
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy (2004) (24)
O-125 ECOG 2597: Phase III study of induction chemotherapy followed by standard thoracic radiotherapy (STD TRT) vs hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer (2003) (23)
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. (2011) (23)
Redefining bronchioloalveolar carcinoma. (2005) (23)
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2013) (22)
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. (2007) (22)
Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. (2005) (21)
The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. (2007) (21)
Similar outcome of elderly patients in Intergroup Trial 0096 (2000) (21)
A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer (1991) (21)
Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer (2006) (21)
Principles and practice of lung cancer: The official reference text of the International Association for the Study of Lung Cancer (IASLC): Fourth edition (2012) (20)
PROLONGED ADMINISTRATION OF ORAL ETOPOSIDE IN PREVIOUSLY TREATED EPITHELIAL OVARIAN CANCER. A PHASE II TRIAL (1992) (20)
Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309) (2003) (20)
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. (2007) (20)
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. (2005) (20)
Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer: phase III study of the eastern cooperative oncology group (ECOG 2597) (2003) (20)
O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma (2003) (19)
A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99 (2008) (18)
A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with Chemotherapy (2004) (18)
Anti-N-methyl-D-aspartate receptor encephalitis in a young woman with a mature mediastinal teratoma. (2010) (17)
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer (2003) (17)
2 Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected 51-3N1-2M0 non-small cell lung cancer (NSCLC): US (1999) (17)
Targeted therapy in non-small cell lung cancer: myth or reality. (2003) (17)
An advance in small-cell lung cancer treatment--more or less. (2003) (17)
Strong Signature of Natural Selection within an FHIT Intron Implicated in Prostate Cancer Risk (2008) (17)
Cytoplasmic Clusterin Expression is Associated With Longer Survival in Patients With Resected Non-Small Cell Lung Cancer (2007) (16)
Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy (2008) (16)
Lung cancer. Introduction. (2003) (16)
Primary Lymphoma of the Central Nervous System: A Report of 20 Cases and a Review of the Literature (1989) (16)
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. (2005) (15)
PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (15)
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. (2003) (15)
The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report (1989) (15)
Targeting the eicosanoid pathway in non-small-cell lung cancer (2009) (15)
Serum Lactate Dehydrogenase and Bone Marrow Metastases in Small-Cell Carcinoma of the Lung (1985) (15)
O-52 ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC (2003) (14)
Chemotherapy for advanced non-small cell lung cancer (2012) (14)
The Role of Hexamethylmelamine in the Combination Chemotherapy of Advanced Ovarian Cancer: A Comparison of Hexamethylmelamine, Cyclophosphamide, Doxorubicin, and Cisplatin (H‐CAP) Versus Cyclophosphamide, Doxorubicin, and Cisplatin (CAP) (1990) (14)
Chemotherapy for resectable stage III non-small-cell lung cancer--can that dog hunt? (1994) (14)
Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non‐small cell lung cancer (1991) (14)
Update on new drugs in small cell lung cancer (2011) (13)
Did targeted therapy fail cyclooxygenase too? (2006) (13)
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial (2005) (13)
Role of chemotherapy for palliation in the lung cancer patient. (2007) (13)
A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group (2009) (12)
Increased dose-intensity in small-cell lung cancer: a failed strategy? (1999) (12)
New drugs in the management of small cell lung cancer (1989) (12)
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. (2005) (12)
A Phase I Study of Vitamin E, 5-Fluorouracil and Leucovorin for Advanced Malignancies (2001) (12)
Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene (2005) (12)
Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (12)
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy (2009) (11)
Treatment of limited-stage small cell lung cancer: recent progress and future directions (1993) (11)
High‐dose, brief duration, multiagent chemotherapy for metastatic breast cancer (1994) (11)
Review: Small-Cell Lung Cancer: Current Perspectives (1987) (10)
Does gefitinib shorten lung cancer survival? Chaos redux. (2008) (10)
Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group. (1986) (9)
Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker: P1-052 (2007) (9)
The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site (1991) (9)
High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial (2017) (9)
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. (2011) (8)
Potential Cost Savings of Oral Versus Intravenous Etoposide in the Treatment of Small Cell Lung Cancer (1992) (8)
Novel therapies for the treatment of non-small cell lung cancer. (2002) (8)
B2-03: Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs) (2007) (8)
PDGFR-beta expression in small cell lung cancer patients. (2007) (7)
O-268 Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus: Prediction and impact of pathologic complete response (CR) (2003) (7)
Daily (D) vs. twice-daily (BID) thoracic irradiation (TI) with concurrent cisplatinietoposide (PE) chemotherapy as initial therapy for patients with limited small cell lung cancer (LSCLC): Preliminary results of a phase III prospective intergroup trial (1994) (7)
A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501) (2006) (7)
Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment (2004) (6)
"The guard dies, it does not surrender!" progress in the management of small-cell lung cancer? (2002) (6)
Thymic malignancies. (2010) (6)
NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
Lung Cancer: Review of the ECOG Experience (1997) (5)
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015) (2000) (5)
Novel strategies for the treatment of lung cancer: modulation of eicosanoids. (2008) (5)
54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial (2003) (5)
Objective responses from adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC) (2000) (5)
Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer (2009) (5)
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. (2008) (5)
Authorship and industry financial relationships: the tie that binds. (2010) (4)
Textbook of Uncommon Cancer, Third Edition (2006) (4)
Models of Lung Cancer Inhibitor AZD 2171 and Fractionated Radiotherapy in Mouse Vascular Endothelial Growth Factor Tyrosine Kinase (2006) (3)
Granulocyte colony-stimulating factor in lung cancer (1993) (3)
An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma (1990) (3)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: (2011) (3)
Ephraim McDowell, the first ovariotomy, and the birth of abdominal surgery. (2010) (3)
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. (2017) (3)
O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer (2003) (3)
PS1371 ELOTUZUMAB IN COMBINATION WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 2 MMRC TRIAL (2019) (2)
P-357 Cyclooxygenase-2 (COX-2) inhibition in advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054) (2003) (2)
O-184 Bronchioalveolar carcinoma: Clinical characteristics and tissue microarray patterns (2003) (2)
Taxanes in lung cancer therapy (1998) (2)
P-628 Trastuzumab in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer: Final report of ECOG 2598 (2003) (2)
Textbook of Uncommon Cancer: Fourth Edition (2012) (2)
Paclitaxel combination chemotherapy in non-small cell lung cancer (1997) (2)
Is chemotherapy for small cell lung cancer beneficial for elderly patients (2000) (2)
O-274 Survival significance of achieving stable disease in chemonaive patients with advanced Non-Small Cell Lung Cancer (NSCLC) treated with standard chemotherapy: Eastern Cooperative Oncology Group (ECOG) data (2003) (2)
Recent advances in the treatment of non-small cell lung cancer with chemotherapy: The ECOG experience (1997) (2)
Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing (2004) (2)
O-158 A randomized phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction therapy (2005) (1)
Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC) (2004) (1)
Improved local control with RSR-13 and concurrent radiation therapy in a phase II study for locally advanced inoperable non-small cell lung cancer (2001) (1)
9 A postoperative protocol reduces opioids prescribed after pediatric orthopaedic surgery (2019) (1)
Cancer control in Cuba: the national cancer control unit. (2010) (1)
Erratum: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer institute of Canada and intergroup trial JBR.10 and a review of the literature (Lung Cancer (2005) 47 (385-394) DOI: 10.1016/j.lungcan.2004.08.016. (2005) (1)
PCN91 ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS: LONGITUDINAL ANALYSES (2011) (1)
Introduction: Non-Small Cell Lung Cancer (2005) (1)
Postoperative radiotherapy in resected non-small-cell lung cancer: Every creek has two banks (2000) (1)
481 ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non small cell lung cancer (NSCLC): Early results and RT quality assurance (QA) (1997) (1)
The NQO 1 * 2 / * 2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer (1)
MS-4 Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial (2004) (1)
Technetium-99m labeled NR-LU-10 monoclonal antibody (MoAb) in assessing patients with carcinoma of the lung (1989) (1)
CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers (2004) (1)
A Phase II Study of Celecoxib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy for Patients With Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (2007) (1)
Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials. (2017) (0)
A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients. (2012) (0)
Ovarian cancer: What is poor prognosis disease? (I: Reply) (1990) (0)
The role of thoracic radiation therapy in small carcinoma of the lung: a concensus report cell (1989) (0)
P-497 A study of differentiation factors as candidate tumor suppressors in lung cancer (2003) (0)
Discussion: Lung cancer (1996) (0)
Weatment of the Elderly Patient with Small-Cell Lung Cancer (2006) (0)
Question-and-Answer Forum (2005) (0)
Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series: Targeting VEGF - Current and future research directions (2005) (0)
Commentary (Chung/Johnson): Targeting the Epidermal Growth Factor Receptor (2006) (0)
OA07.05 High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials (2019) (0)
The Saba/Khuri/Shin article reviewed (2006) (0)
lymphoma: preliminary observations combination chemotherapy on posttherapy fertility in male patients with Effect of a luteinizing hormone releasing hormone agonist given during (2011) (0)
176 P27 is a molecular tumor marker prognostic for survival in 118 NSCLC patients (PTS) treated with radiation t chemotherapy on ECOG3590 (2006) (0)
Commentary (Laskin/Johnson): Chemotherapy for Non–Small-Cell Lung Cancer (2003) (0)
The authors reply [5] (2007) (0)
P-252 Interim report: A phase III randomized double blindchemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer (2005) (0)
Chemotherapy for the palliation of lung cancer (2008) (0)
APhase II Study of Celecoxib in Combinationwith Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/BNon^Small Cell Lung Cancer (2009) (0)
TargetedTherapies in Combinationwith Chemotherapy in Non ^ Small Cell Lung Cancer (2006) (0)
Lung Cancer: Principles and Practice (2011) (0)
Discussion: Evaluation of Current Clinical Status and Future Directions in Small Cell Lung Cancer (1992) (0)
Current Management Strategies in Intracranial Breast Cancer Metastasis (2008) (0)
Phase I Trial of Retroviral BRCA 1 sv Gene Therapy in Ovarian Cancer 1 (2005) (0)
Effectiveness of treatment for non-small cell lung cancer (Reply) (1990) (0)
Seminars in oncology. Introduction. (2002) (0)
Sample size determination for the two-stage design of a phase II cancer clinical trials with correlated unbalance binary endpoints (1998) (0)
Clinical Targeting of VEGF and EGFR Effective in Non-Small Cell Lung Cancer (2004) (0)
P1-185: Progress report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase iii randomized double blind chemoprevention trial of selenium supplementation in resected stage i non small cell lung cancer (2007) (0)
ZD1839 (Iressa™): A new targeted therapy for solid tumors. Foreword (2002) (0)
O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib (2005) (0)
Advances in Management of NSCLC - Advances in Chemotherapy: PL3-01 (2007) (0)
An Unexpected Lesson in Quality Improvement: High-reliability intervention intended for asthma guidelines reduces chest x-rays in bronchiolitis. (2019) (0)
Phase I I S tudy o f I rinotecan P lus C isplatin i n P atients With A dvanced N on-Small-Cell L ung C ancer (1999) (0)
Factors influencing the career decisions of United States hematology oncology fellows training at NCI- and NCCN-designated cancer centers. (2010) (0)
Cancer Small Cell Lung − in Non α via Hypoxia-Inducible Factor-1 Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 Updated (2005) (0)
Usefulness of collecting individual data in meta-analyses (1991) (0)
IIIB.1 Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup JBR.10 (2006) (0)
P3-066: The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib (2007) (0)
Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC). (2013) (0)
Contents, Supplement 1, 1992 (1992) (0)
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population. (2022) (0)
Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. (2009) (0)
Keynote comment: Cancer drug pricing in the USA. (2006) (0)
Eicosanoids in non-small cell lung cancer (NSCLC). (2010) (0)
Multi-Institutio nal P hase I /II T rial o f P aclitaxel, Cisplatin, a nd E toposide W ith C oncurrent R adiation f or Limited-Stage S mall-Cell L ung C arcinoma (2000) (0)
Prophylactic cranial irradiation: Treating the patient or the physician? (1998) (0)
Meaningful Subset Analyses Contribute to Optimal Patient Care (2008) (0)
Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10 (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David H. Johnson?

David H. Johnson is affiliated with the following schools:

Dalhousie University
Vanderbilt University
University of Toronto
University of Texas Southwestern Medical Center
University of Pennsylvania
Heidelberg University